Skip to main
TMCI
TMCI logo

TMCI Stock Forecast & Price Target

TMCI Analyst Ratings

Based on 5 analyst ratings
Hold
Strong Buy 20%
Buy 0%
Hold 80%
Sell 0%
Strong Sell 0%

Bulls say

Treace Medical Concepts Inc is positioned for potential revenue growth due to its innovative product offerings, particularly the Lapiplasty 3D Bunion Correction procedure and the new MIS Osteotomy system, which may gain greater traction in the market than previously estimated. The company has opportunities to increase revenue per procedure through enhanced sales of ancillary products, indicating a potential for improved financial performance. Furthermore, there is an increasing likelihood of a growth acceleration trajectory anticipated in the second half of 2025 through 2026, supported by the company's strategic updates and expanded offerings.

Bears say

Treace Medical Concepts is facing potential pricing pressures on its patented Lapiplasty 3D Bunion Correction procedure, which could jeopardize revenue estimates if these pressures are worse than anticipated. Additionally, the profitability of Lapiplasty for healthcare providers may not be as compelling as alternative procedures, such as traditional Lapidus Fusion and Osteotomies, potentially hindering the adoption rate of this technology. These factors contribute to a negative outlook on the company's financial performance and growth prospects in the competitive orthopaedic market.

TMCI has been analyzed by 5 analysts, with a consensus rating of Hold. 20% of analysts recommend a Strong Buy, 0% recommend Buy, 80% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Treace Medical Concepts and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Treace Medical Concepts (TMCI) Forecast

Analysts have given TMCI a Hold based on their latest research and market trends.

According to 5 analysts, TMCI has a Hold consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Treace Medical Concepts (TMCI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.